Last reviewed · How we verify
Deficiency of aromatic-L-amino-acid decarboxylase
Approved treatments
- Upstaza · PTC Therapeutics International Limited
Upstaza works by replacing the deficient enzyme aromatic-L-amino-acid decarboxylase.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Deficiency of aromatic-L-amino-acid decarboxylase patent landscape — cliff calendar, originator estates, attackable patents
- Deficiency of aromatic-L-amino-acid decarboxylase treatment landscape brief
- Deficiency of aromatic-L-amino-acid decarboxylase treatment updates RSS
Frequently asked questions about Deficiency of aromatic-L-amino-acid decarboxylase
What drugs treat Deficiency of aromatic-L-amino-acid decarboxylase?
Tracked treatments include Upstaza.
What is the treatment for Deficiency of aromatic-L-amino-acid decarboxylase?
Standard treatment for Deficiency of aromatic-L-amino-acid decarboxylase includes Upstaza. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Deficiency of aromatic-L-amino-acid decarboxylase patent cliff · Deficiency of aromatic-L-amino-acid decarboxylase CI report
- Treatment: Upstaza · PTC Therapeutics International Limited
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing